Last reviewed · How we verify
Nimenrix (GSK134612 vaccine)
Nimenrix is a vaccine that induces immunity against meningococcal disease.
Nimenrix is a vaccine that induces immunity against meningococcal disease. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.
At a glance
| Generic name | Nimenrix (GSK134612 vaccine) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the body's immune system to produce antibodies against the meningococcal bacteria, providing protection against invasive meningococcal disease.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y
Common side effects
- Pain, redness, swelling, or itching at the injection site
Key clinical trials
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children (PHASE3)
- Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects (PHASE3)
- Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children (PHASE3)
- Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children (PHASE3)
- Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers (PHASE3)
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (PHASE3)
- Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nimenrix (GSK134612 vaccine) CI brief — competitive landscape report
- Nimenrix (GSK134612 vaccine) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI